The most interesting shift: Pharma is no longer focused on managing diabetes alone
Discontinuation and weight regain How often people stop the medication TRIUMPH-4 (n=445, 68 weeks, obesity with knee osteoarthritis): 18.2% on 12 mg, 12.2% on 9 mg, 4% on placebo 2 TRANSCEND-T2D-1 (n=537, 40 weeks, type 2 diabetes): 5.1% on 12 mg, 4.5% on 9 mg, 0% on placebo 3 Phase 2 (n=338, 48 weeks): 6 to 16% across doses, 1% on placebo 1 For comparison, Wegovys STEP-1 trial reported a discontinuation rate of around 7% due to side effects, and Mounjaros SURMOUNT-1 reported a similar rate
Handling Tips Always wash your hands before handling the vial
Always report suspected side effects through the Yellow Card Scheme (yellowcard.mhra.gov.uk) to contribute to ongoing medication safety surveillance
Fill out this short form and a representative will contact you within 24 hours
[ CrossRef ] [ Google scholar ] [ PubMed ] Dou Z, Berger SL